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Abstract 
Hibernation is an adaptation that allows the Arctic ground squirrel (Urocitellus parryii) to 
survive the harsh arctic winter. Recently the activation of the Adenosine A1 receptor (A1AR) has 
been shown to be necessary for entrance into hibernation during the winter but not summer 
season. In the current study we characterize the A1AR in the forebrain, hippocampus and 
hypothalamus of summer and winter AGS. We also tested the hypothesis that increased A1AR 
agonist efficacy is responsible for increased sensitization of the A1AR during the winter season. 
The resulting 35S-GTPγS binding data indicated an increase in agonist potency during the winter 
season in all three brain regions. A plausible explanation of our results is that increased potency 
in the forebrain during the winter season is due to an increase in efficacy as indicated by a 
greater number of receptors in the high affinity state. In addition 35S-GTPγS binding, [3H] 
DPCPX saturation and competition assays establish for the first time pharmacological 
characteristics such as EC50, Kd, Kilo and Kihi in AGS brain.  
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Introduction 
Hibernation is an adaptation that allows an animal to survive times of low resource availability 
by going into a suspended animation like state. During hibernation, hibernators such as the 
Arctic ground squirrel (AGS; Urocitellus parryii) drastically decrease core body temperature and 
enter a hypometabolic state (Williams et al., 2012, Buck and Barnes 2000). Several studies have 
been conducted to ascertain the mechanisms that facilitate the hibernation state without a 
definitive answer (Dawe and Spurrier, 1972, Kondo and Kondo, 1992, Oeltgen et al., 1987). 
Despite these studies, it is still largely unknown what mechanisms are responsible for entrance 
into hibernation. Here past studies on hibernation induction triggers will be reviewed.  
In the 1970’s it was found that blood serum from hibernating 13-lined ground squirrel (Citellus 
tridecemlineatus) triggered hibernation in summer 13-lined ground squirrels two to twenty-two 
days post injection (Dawe et al., 1970).  This unknown factor in the hibernator’s serum was 
deemed the hibernation initiation trigger (HIT). Further experimentation showed that the timing 
of blood collection from the hibernators influenced how fast the summer euthermic animals 
entered hibernation (Dawe and Spurrier, 1972). It was determined that serum from a woodchuck 
(Marmota monax) in a long torpor bout caused summer 13-lined ground squirrels to enter 
hibernation in less time than serum from the same squirrel in a short torpor bout.  In addition to 
this discovery it was determined that blood from a 13-lined ground squirrel in intermediate 
arousal did not induce torpor. This indicates that the HIT increases in concentration during 
deeper hibernation bouts and is not active during arousal.  The authors also found that serum 
from winter animals that underwent dialysis and mixed with summer euthermic blood was not 
able to induce torpor.  When the hibernation serum dialysate was diluted and then injected the 
summer animals went into hibernation. The authors conclude that there is a factor in the summer 
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animal blood that causes the deactivation of the HIT. This discovery leads to the question of why 
the summer euthermic animals underwent hibernation when the factor that deactivates the HIT 
should be expressed. One possible explanation is that the HIT induces a cascade of events that 
leads to either an increased expression of the HIT or a decrease in the inactivation component.  
Analysis of Asian Chipmunk (Tamias sibiricus) serum proteins using gel permeation high-
performance liquid chromatography revealed a 140-kDa complex of four proteins called 
hibernation protein (HP), HP-20, -25,-27 and -55 (Kondo and Kondo 1992).  These proteins 
disappear when the hibernation season starts. In addition to Asian Chipmunks, these proteins 
were found in 13-lined ground squirrels but were not evident in non-hibernating species.  This 
would indicate that control over the hibernation is due to a complex that inactivates several 
proteins.  The protein complex could break apart due to an unidentified enzyme making its 
constitutive parts active.  Interestingly, the authors of this paper find that the HPs do not reappear 
in the blood during inter-bout arousals. This indicates that plasma HPs are not required for 
arousal.  Since the HPs were not found in the blood of hibernating animals, it seems unlikely that 
the blood would cause entrance into hibernation during the winter. A possible explanation for 
this is that 140-kDa HP complex could act as an inhibitory control over the HIT, allowing the 
animal to enter hibernation without changing the concentration of the HIT protein. This would 
have enabled the HIT to go unnoticed due to the authors’ interest in the changes in protein 
expression between hibernation and summer animals. Follow-up studies indicated that the HIT 
complex was migrating to the brain during the entrance into hibernation (Kondo et al., 2006). 
The authors also found that administration of an antibody against HP-20 during hibernation 
shortened the hibernation bout. This indicates that HPs are important for entering into the 
hibernation state. Woodchuck albumin was also analyzed for the existence of the HIT protein 
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using 2-d gels and column chromatography (Horton et al., 1998).  Two different proteins were 
found that had differential expression in regard to season, an 88kDa winter specific protein and a 
77kDa summer specific protein.  Partial sequencing of the 88kDa protein showed an alpha 1-
glycoprotein like structure, with low affinity for the delta opioid receptor (Ki = 15813 +/- 
2216nM).  The authors do not test other receptor populations for affinity.  It is interesting that 
Asian Chipmunks have an inhibitory 140kDa protein complex and Woodchucks have unique 
proteins. This discrepancy could be due to the use of different techniques or that the strategy for 
entering hibernation is species specific.  
The discovery of unique proteins expressed in hibernation lead to several studies focused on 
determining the mechanism of action of the HIT. The opioid system became of interest due the 
fact that the injection of high doses of opiates causes a depression of body temperature (reviewed 
in Clark 1979). It was determined that 13-lined ground squirrels that received the opioid receptor 
antagonist naloxone delivered through an osmotic mini-pump over 28 days showed a decreased 
number of hibernation bouts when injected with blood serum from bears (Bruce et al., 1987).  
Upon removal of naloxone the 13-lined ground squirrels started to show hibernation bouts 
similar to control animals. This data indicates that the opioid system is involved in the entrance 
into hibernation. However, it is interesting to note that the animals were still able to undergo 
hibernation.  Naloxone has high affinity for the delta opioid receptors and lower affinity for the 
Mu and Kappa receptors. This could mean that the delta opioid receptor is only partly involved 
and that the actions of HIT are through either the Mu or the Kappa opioid receptors. Further 
study into the opioid system revealed that hibernation was not inducible in the summer through 
the kappa opioid receptor using woodchuck serum (Oeltgen et al., 1987).  Subsequent studies 
into the opioid system revealed that stimulating the delta opioid receptor with D-Ala2-D-Leu5 
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enkephalin (DADLE) induced hibernation in a similar degree as woodchuck serum (Oeltgen et 
al., 1988). This response was slightly different for the mu and kappa opioid agonists, which 
induced hibernation to a much lesser degree then DADLE.  Interestingly, upon injection of 
woodchuck serum both kappa and mu opioids decreased the hibernation bouts when compared to 
saline and woodchuck serum.  Although this work points to the idea that hibernation is induced 
by the delta opioid receptors, there are several topics to consider.  First, the authors indicate that 
the 13-lined ground squirrels were trapped in the wild in the summer, but do not indicate when 
the animals were used in their experiment. Knowing the timing of the experiment is important 
because it took the animals a minimum of five days and a maximum of nineteen days, which 
could put the animals into the hibernation season.  If this is the case then it would be difficult to 
separate normal from DADLE induced hibernation bouts. Another point to consider is the 
authors did not reverse the effects of DADLE or HIT using an antagonist. This leads to the 
question of whether or not the effects seen are specific to the opioid receptors.  
Recently, the metabolite adenosine has been implicated in the entrance into hibernation during 
the hibernation season in Arctic ground squirrels (Jinka et al., 2011).  The researchers in this 
study find that intracerebroventricular administration of the A1AR agonist N
6-
Cyclohexyladenosine (CHA) induced hibernation reliably during the mid-season of hibernation.  
CHA did not induce hibernation in the summer season and unreliably in the early hibernation 
season where only one third of the animals entered hibernation.  The authors were also able to 
reverse entrance into hibernation using an A1 receptor (A1AR) antagonist, providing further 
support that the A1AR is important for the entrance into torpor.  One noteworthy aspect of this 
experiment is that CHA did not induce hibernation after the first hibernation bout, which is odd 
considering the system for entrance into hibernation should already be expressed.  An 
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explanation for these results is that the A1AR could be acting in parallel of another receptor 
system that is inducing hibernation. That would mean that as the season progresses, the A1AR 
could be up regulated to have a greater effect on the organism.  Conversely, a down regulation of 
a receptor that has inhibitory action on the A1AR would have the same effect. The second 
explanation is supported by research done on the distribution of A1AR in the Columbian ground 
squirrel (Lee et al., 1993). The authors used autoradiographic binding studies to determine the 
A1AR concentration in several brain regions including the midbrain and hypothalamus. The 
hypothalamus showed no difference in concentration of A1AR or adenosine. Due to the static 
nature of the A1AR and adenosine concentration it is likely that the sensitization is due to the 
decoupling of another receptor type. Although the authors found no difference in the 
hypothalamus they did show a difference in the midbrain. Note that the autoradiographic binding 
data was conducted in a different species than the AGS, which could have a different mechanism 
of entrance into hibernation. This is unlikely however since A1AR regulates onset of torpor in 
hamsters and AGS suggesting a universal A1AR mechanism (Tamura et al., 2005). Another 
research group found increased expression of c-Fos, an indicator of neuronal activity in the 
medial preoptic area of the hypothalamus during the entry phase of the hibernation bout in 13-
lined ground squirrels (Bratincsak et al., 2007).  This is interesting due to the medial preoptic 
area of the hypothalamus being implicated in the control of thermoregulation.  Additional 
information about the induction of hibernation through an A1AR mechanism is scarce.  
In the current study, the A1AR was characterized in summer and winter season AGS to 
investigate the mechanism of A1AR seasonal sensitization.  To achieve our goal, A1AR agonist 
affinity and potency was determined. In order to interpret the results it is necessary to review 
how an agonist binds to the A1AR and the effects of synergistic binding.  
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A1AR is part of the seven trans-membrane G-protein coupled receptor family (GPCR).  GPCRs 
are characterized by an N-terminal extracellular end, a C-terminal intracellular tail and a peptide 
chain that snakes through the membrane and forms the seven trans-membrane domains.  In order 
to propagate the external signal, the C-terminal tail binds with a G-protein complex made up of a 
Gα, Gβ, and Gγ subunit.  In the absence of stimulation the Gα subunit of the G-protein complex is 
bound to guanosine diphosphate (GDP). The presence of an agonist induces conformational 
changes to the receptor and, in turn, to the G-protein complex.  This decreases the Gα subunits 
affinity for GDP and increases it for guanosine-5’-triphosphate (GTP).  GTP binding induces the 
release of the G-protein complex from the C-terminus and the disassociation of the G-protein 
complex into a Gα-GTP and a Gβ /Gγ dimer.  The extracellular signal is propagated by both the 
GαGTP and the Gβ /Gγ dimer.  The signal is halted when GTP is hydrolyzed to GDP allowing the 
reformation of the G-protein complex.  
The first step in extracellular signal transduction takes place when the agonist binds to the 
receptor. It has been shown that transmembrane helixes 6 and 7 (TM6 and TM7) are involved in 
the formation of the agonist binding pocket (Olah et al., 1994). The amino acid residues of 
transmembrane helix 3 interact with the adenine group of the adenosine molecule (Rivkees et al., 
1999).  In addition, the residues in transmembrane helix 2 have been shown to be necessary for 
recognition of the ribose group (Xie et al., 2006). 
Several GPCRs have been shown to form functional heteromers with the A1AR. Stimulation of 
the excitatory adenosine A2A receptor (A2AAR) in the A2AAR/A1AR heteromer decreases agonist 
binding and efficacy (Ciruela et al., 2006, Casadó et al., 2010).  The A1AR also forms 
heteromers with the purinergic P2Y1 receptor (P2Y1R) in several cell types (Yoshioka et al., 2002, 
Tonazzini et al., 2008, Tonazzini et al., 2007). Activation of the A1AR in the P2Y1R / A1AR 
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heteromer led to increased activation of the P2Y1R while a P2Y1R agonist decreased activation of 
the A1AR.  Stimulation of purinergic P2Y2 receptor (P2Y2R) in the P2Y2R/ A1AR heteromer had 
similar effects as the P1Y1R but the P2Y2R showed enhanced activity in the absence of A1AR 
activation (Suzuki et al., 2006).  The metabotropic glutamate 1α receptor (mGlu1α)/ A1AR 
heteromer resulted in increased efficacy of the mGlu1α with decreased N-methyl-D-aspartate 
(NMDA) toxicity (Gines et al., 2000).  
In addition to other GPCRs, small proteins can bind synergistically with the A1AR and induce 
changes in binding properties. Thus far three such proteins have been identified, adenosine 
deaminase, Cytoskeletal protein 4.1G and heat shock cognate protein 73 (hsc 73). ADA, an 
enzyme that metabolizes adenosine to inosine, has been shown to promote the A1AR into a high 
affinity state in several cell types independent of ADA activity (Ciruela et al., 1996, Saura et al., 
1996).  Cytoskeletal protein 4.1G and heat shock cognate protein 73 (hsc 73) interact with the 
third intercellular loop of the A1AR and inhibited ligand binding (Sarrio et al., 2000, Lu et al., 
2004).   Hsc 73 binding was decreased in a dose response manner when in the presence of ADA.  
Although synergistic effects on A1AR are important aspects of how the extracellular signal is 
translated, internalization is another way external signals can be controlled. Generally GPCRs 
are internalized through receptor phosphorylation which promotes G-protein complex 
dissociation and rapid internalization in a vesicle. The A1AR has a low basal level of 
phosphorylation and, in the presence of an agonist, the level of phosphorylation stays static (Gao 
et al., 1999, Ciruela et al., 1997).  Internalization studies indicated that A1AR cluster into 
caveolin like structures after 5-12h of chronic agonist stimulation (Escriche et al., 2003).   The 
A1AR is then sorted into vesicles and either degraded or recycled to a non caveolar location at 
the cell surface.  The rate of internalization is affected by allosteric modulation but not by 
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palmitate attachment (Ferguson et al., 2002).  ADA internalizes along with the A1AR but is 
separated and recycled to a different membrane site than the A1AR.  ADA, Hsc 73 and 
cytoskeletal protein 4.1G both promote internalization of the A1AR.   
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Methods and Materials 
Arctic Ground Squirrels 
AGS tissue was obtained from a tissue bank (courtesy of B. Barnes). All animals were 
euthanized under protocols approved by the UAF IACUC. AGS were captured near 66°38′N, 
149°38′W under permit from the Alaska Department of Fish & Game.  
Animals were housed at 22°C on an 18:6 day: night cycle (5/2011-8/2011) and at 2°C on a 4:20 
day: night cycle (8/2011-1/2011).  Hibernation was monitored using the “shavings added” 
method where hibernation (torpor) is indicated when shavings placed on the back of the AGS 
remain undisturbed 24h later (Lyman, 1948; Pengelley and Fisher, 1961). All tissue was 
harvested from adult male AGS during the summer or winter season. Winter season was defined 
by evidence of spontaneous hibernation (torpor). Winter AGS were euthanized without being 
aroused from torpor after demonstrating six to eleven torpor bouts and at least ten but not more 
than thirteen days in the current torpor bout.  Summer season animals were defined as AGS that 
were captured after the 2010-2011 hibernation season and kept in captivity for two months 
before being euthanized.  
Summer AGS were euthanized by decapitation under a surgical plane of anesthesia. Winter 
animals were hibernating and did not require anesthesia. Immediately following euthanization 
the brain was removed and the forebrain, hippocampus, and hypothalamus were isolated and 
frozen in liquid nitrogen.    All tissue was stored at -80oC until use.  
Isolation of Plasma Membrane for 35S GTPγS and [3H]DPCPX Binding Experiments 
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AGS membrane from forebrain, hippocampus, hypothalamus and brainstem were isolated as 
described previously with modifications (Giuntini et al., 2004).  For membrane isolation protocol 
refer to appendix A. Briefly, tissue was homogenized on ice using an all glass Dounce 
homogenizer (10-15 strokes) in 20X volume homogenization buffer containing 10 mM HEPES, 
2 IU/mL ADA, 640 mM sucrose and protease inhibitor tablets (Roche, Indianapolis, IN) and then 
further homogenized by polytron for 10-15 sec. The suspension was centrifuged at 1000 x g for 
10 min at 4oC. Resultant supernatant was centrifuged at 48000 x g for 15 min at 4oC.  Pellets 
were resuspended in Resuspension buffer containing 10 mM HEPES, 2 IU/mL ADA and 
protease inhibitor tablets.  Suspension was centrifuged at 48000 x g for 15 min at 4oC.  Pellets of 
AGS hippocampus and hypothalamus were suspended in a solution containing 6 mM HEPES, 
122 µM GDP and 2.4 IU/mL ADA, the forebrain was suspended in 6mM HEPES, 77 µM GDP, 
and 0.5 IU/mL ADA and both were incubated at room temperature under gentle rocking for 60 
min and then centrifuged at 48000 x g for 30 min. Subsequent pellets were resuspended in 
Resuspension buffer and stored at -80oC until use.  
35S-GTPγS Binding 
35S-GTPγS binding experiments were performed as described previously with modifications 
(Giuntini et al., 2004). For detailed protocols refer to appendix B. On the day of the experiment, 
aliquots of summer and winter AGS were thawed on ice. The protein content was then 
determined by protein analysis (Bio-Rad, Hercules, CA) followed by centrifugation at 48000 x g 
for 30 min at 4oC.  The pellet was then resuspended in previously optimized Assay buffer (refer 
to appendix C for optimization data) containing 50 mM HEPES, 200 mM NaCl, 10 mM MgCl2, 
40 µM GDP, 100 µM Saponin, 1 IU/mL ADA and 1 mM DTT, at pH 7.4. 100 µg per ml protein 
was incubated with 400 pM of 35S-GTPγS in a total volume of 100 µL for 90 minutes (refer to 
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appendix D for binding kinetics) under gentle rocking at 27oC. Non-specific activity was 
determined in the presence of 5 µM GTPγS. Constitutive activity was defined as binding in the 
absence of CHA. The reaction was terminated by rapid vacuum filtration and then each well was 
washed three times with 200 µl of ice cold 50 mM HEPES. The plate was allowed to dry 
overnight. 40 µL of scintillation cocktail (PerkinElmer, Waltham, MA) was added to each well 
and 35S activity was determined in a 1450 Microbeta plus microplate scintillation counter 
(PerkinElmer, Waltham, MA) utilizing a one minute counting time.  The effect of the A3AR was 
determined by preincubating the membrane on ice with an A3AR antagonist (MRS 1334, 500 
nM) or agonist (Cl-IB-MECA, 132 nM) for at least one hour before conducting the 35S-GTPγS 
binding experiment.  
 [3H]DPCPX Binding 
Saturation experiments to determine the Kd and Bmax of [3H] DPCPX binding to A1AR were 
conducted on the membrane of the forebrain, hippocampus and hypothalamus of winter and 
summer AGS following the guidelines of (Hulme and Trevethick 2010) with modification. For 
binding protocols refer to appendix E. On the day of the experiment, aliquots of summer and 
winter AGS were thawed on ice.  Protein content of each animal was determined by protein 
analysis (Bio-Rad, Hercules, CA) followed by centrifugation at 48000 x g for 30 min at 4oC. The 
pellet was then resuspended in a solution containing 50 mM HEPES and 2 IU/ml ADA. 
Saturation experiments were performed by incubating 100 µg/ml protein with nine 
concentrations of [3H] DPCPX ranging between 0.4 and 30 nM in the presence of 50 mM 
HEPES and 2 IU/mL ADA.  Non-specific binding was defined in the presence of 7µM CPT.  
The solution was allowed to incubate for 90 minutes at room temperature and membrane bound 
ligand was isolated as described below.  
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KiLo was determined by displacing 1 nM [
3H] DPCPX with nine concentrations of CHA ranging 
between 100 pM and 10 µM in the presence of 100 µg/mL protein, 50 mM HEPES, 2 IU/mL 
ADA and 1 mM GTP. KiHi was defined by displacing 1 nM [
3H] DPCPX (PerkinElmer, 
Waltham, MA) with CHA in the same manner as the KiLo experiments but without GTP. The 
solution was allowed to equilibrate for 90 minutes at room temperature as indicated by kinetic 
experiments (sup. info).  Free and bound [3H] DPCPX was separated through an Inotech glass 
fiber filter pad (0.35 mM thickness/0.75 µM retention) (Inotech Bio. Sys., Derwood, MD) by 
rapid filtration (0.5 ml per sec per well) with a cell harvester (Tomtec, Hamden, CT). The filter 
was then allowed to dry overnight. The next morning each well was isolated and placed in a 
scintillation vial.  Scintillation cocktail (PerkinElmer, Waltham, MA) was added and 
radioactivity was determined (1450 Microbeta Plus, PerkinElmer, Waltham, MA) with a five 
minute count per well.   
Data analysis 
35S-GTPγS specific binding was determined by subtracting non-specific binding from overall 
binding. Specific binding was converted to percent over constitutive receptor activity. pEC50, 
Hill slope and span were determined using the function Log(agonist) vs response – variable slope 
(four parameters) in Graphpad Prism 5 (v 5.04) (Graphpad Software, La Jolla, CA). 
[3H] DPCPX bound was converted from cpm to fmol per mg protein and the specific binding 
was calculated. A sum of squares F-test was used to determine if a one site or two site model was 
appropriate.  Kd and Bmax were determined with Graphpad Prism (one or two site –total and 
nonspecific).  KiLo for the displacement of [
3H] DPCPX in the presence of GTP was calculated 
using the average Kd (one or two site – Fit Ki). KiHi was calculated for the displacement of [3H] 
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DPCPX without GTP (one or two site – Fit Ki) using the average Kd and KiLo. Statistical 
differences were established between summer and winter AGS within the same tissue by way of 
a Student t-test (Excel 2013) with a threshold of p < 0.05. Standard error is expressed as standard 
error of the mean (SEM).  
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Results 
Summer and Winter AGS were euthanized during the appropriate season and then the binding 
parameters of the A1AR were investigated in three different tissues by probing agonist induced 
GDP/GTP exchange by way of 35SGTPγS binding assay, [3H]DPCPX saturation experiments and 
[3H]DPCPX displacement by CHA in the presence or absence of GTP.  
The effect of CHA on 35S GTPyS binding in forebrain tissue from AGS collected in the summer 
season was determined over a range of 100 pm to 100 µM (Fig. 1).  The resulting data indicated 
a Hill slope of less than 0.4.  In order to ascertain if the broad range of CHA concentration was 
evoking binding at more than one site and thus contributing to the low Hill slope, the data was 
reanalyzed while constricting the highest CHA concentration to 1µM.  The results returned an 
increase in hillslope to greater than 0.6.  In subsequent experiments, CHA concentration was 
constrained between 100pM to 1µM which yielded a hillslope of greater than 0.9.  Unless stated 
otherwise, all other 35S-GTPyS binding experiments were restricted to a CHA concentration 
range of 100 pm to 1 µM.  
A1AR agonist induced GDP/GTP exchange was then investigated in the forebrain, hippocampus 
and hypothalamus of summer and winter AGS (Fig. 2). As expected from the above results, 
CHA stimulated GDP/GTP exchange in a single site manner.  The pEC50 of CHA in both the 
hippocampus (7.08 ± 0.050, 7.24 ± 0.030 summer, winter) and hypothalamus (7.07 ± 0.054, 7.27 
± 0.071 summer, winter) was greater in the winter which is indicative of an increase in the 
potency of CHA. The same effect was not seen in 
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Fig. 1.1 The effect of dose-range on CHA induced GDP/GTP exchange in AGS forebrain. At 
concentrations greater than 100 μM CHA demonstrates a Hill slope of 0.39 ± 0.015 (n=5) (A). 
Subsequent reanalysis with a maximum CHA dose of 1 μM returned a Hill slope of 0.63 ± 0.070 
(n = 5) (B). Repeating the experiment with a maximum dose of 1 μM resulted in a Hill slope of 
0.93 ± 0.018 (n=6) (C). Visual representation of change of Hill slope (D). 
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Fig. 1.2 CHA induced GDP/GTP exchange in summer and winter AGS brain tissue. Three brain 
tissues were analyzed: forebrain (6,5 summer, winter) (A), hippocampus (n= 7,7 summer, 
winter) (B) and hypothalamus (n=7,6 summer, winter) (C).  Analysis of the curves for pEC50 
indicated an increase in the potency of CHA in the hippocampus and hypothalamus of winter 
season AGS (D).  There was no difference in Rmax (E).  Winter graphs have a similar shape as 
the summer graphs. * indicates statistical difference (p < 0.05) compared to summer tissue. 
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the forebrain (7.80 ± 0.035, 7.79 ± 0.054 summer, winter). None of the tissue displayed a 
difference in the Rmax between the winter and summer groups. Subsequent follow up 
experiments in the forebrain with PIA,an A1AR agonist, stimulated GDP/GTP exchange in a 
single site manner and did demonstrate an effect of season on potency (7.46 ± 0.033, 7.59 ± 
0.042 summer, winter) (Fig. 3).  
To further characterize the A1AR and to determine if a change in affinity or efficacy was driving 
the seasonal effect on potency, saturation and displacement assays were conducted in the three 
different brain regions.  Saturation experiments using [3H] DPCPX indicated a single site model 
and yielded Kd and Bmax values that did not differ between groups of animals (Fig. 4, refer to 
appendix F for more figures). CHA displaced [3H] DPCPX  in a two-site model indicating a KiHi 
and KiLo (Fig 5). In the presence of GTP only the KiLo site was detected.  KiLo values determined 
by CHA displacement of [3H] DPCPX in the presence GTP and KiHi values determined in the 
absence of GTP were also found to be similar between groups (Table 1).  Efficacy, measured by 
the GTP-induced shift in Ki defined as the ratio of KiHi to Kilo, likewise did not differ between 
groups. One result consistent with increased efficacy of CHA in winter animals was noted by a 
higher fraction of receptors in the high affinity state in the forebrain from winter animals. We 
next investigated the low Hill slope seen at concentrations of CHA exceeding 1µM in the 
forebrain of summer and winter AGS. It has been established that CHA has low affinity for the 
A3AR in the rat brain (Mazzoni et al., 1995). We therefore hypothesized that CHA at 
concentrations above 1 µM was stimulating the A3AR. In order to test this hypothesis we 
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Fig. 1.3 PIA induced GDP/GTP exchange in the 
forebrain of summer AGS (A). PIA demonstrated 
an increase in potency in the winter season 
without effecting the Rmax (n=6,5) (B). * 
indicates statistical difference (p < 0.05) 
compared to summer tissue.  
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Fig. 1.4 Kinetics of [3H] DPCPX binding in summer and winter AGS.  
The saturation curve of DCPX in the forebrain of summer (A) was 
similar to that obtained in the winter season (n= 6,5 summer, winter) as 
well as the hippocampus (n= 8,6 summer, winter) and hypothalamus 
(n= 5,5 summer, winter) (not shown). [3H] DPCPX demonstrated 
nanomolar affinity for the A1AR in the three tissues tested with no 
effect of season (B). The number of A1AR in the forebrain, 
hippocampus and hypothalamus (C) were similar with no indication of 
a seasonal effect. 
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Fig. 1.5 [3H] DPCPX displaced with CHA in the presence 
or absence of GTP. Summer forebrain binding curves were 
best fit by a two-site model in the absence of 1 µM GTP 
(A) and one-site in the presence of 1 µM GTP (B).  The 
general characteristics of these graphs were conserved in 
the winter season of the forebrain as well as the 
hippocampus and hypothalamus (not shown/Sup info). 
 
 
 
 
 22 
 
Table 1.1 Parameters of the displacement of [3H] DPCPX AGS brain tissue. The ability for CHA 
to displace [3H] DPCPX was similar in the forebrain (n= 6,5 summer, winter), hippocampus (n= 
8,6 summer, winter) and hypothalamus (n= 5,5 summer, winter) .  KiHi and KiLo values were 
independent of season in all three tissues tested.  The fraction of receptors in the high affinity 
state increased during the winter season in the forebrain but not the hippocampus or 
hypothalamus. * indicates statistical difference (p < 0.05) compared to summer tissue.  
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blocked the A3AR with a single concentration of MRS 1334, an A3AR antagonist, before 
assessing agonist stimulated GDP/GTP exchange by 35S-GTPγS binding assay with up to 100 
µM CHA (Fig. 6). The resulting data indicated that MRS 1334 had no effect on the Hill slope in 
either the summer (0.345 ± 0.021, 0.391± 0.019 DMSO, MRS 1334) or winter (0.430 ± 0.030, 
0.482 ± 0.025 DMSO, MRS 1334).  MRS 1334 treated tissue did display a decrease in pEC50 of 
the same magnitude in both the summer (7.78 ± 0.073, 7.26 ± 0.038 DMSO, MRS 1334) and 
winter (7.95 ± 0.040, 7.26 ± 0.021 DMSO, MRS 1334). Although the change in potency was 
similar between the winter and summer seasons, the winter tissue treated with MRS 1334 
displayed an increase in Rmax compared to winter DMSO treated tissue.  
We next investigated the effect of stimulating A3AR with Cl-IB –MECA on agonist stimulated 
GDP/GTP exchange with up to 1µM of CHA in the forebrain of summer AGS (Fig. 7). The 
resulting data indicated no difference in the presence or absence of Cl-IB-MECA in any of the 
binding parameters. 
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Fig.1.6 CHA induced GDP/GTP exchange in the presence of A3AR antagonist. MRS 1334 had 
no effect on the hill slope of CHA induced GDP/GTP exchange in either the forebrain of summer 
(n= 3,3 DMSO, MRS 1334) (A) or winter (n= 3,3 DMSO, MRS 1334) (B) season at a range of 
100pM to 100µM suggesting the slow hill slope was not due to CHA binding to both the A1AR 
and the A3AR.  MRS 1334 reduced the potency of CHA by the same magnitude in both the 
summer (C) and winter (D) season. In the winter MRS 1334 induced an increase in Rmax when 
compared with DMSO. * indicates statistical difference (p < 0.05) compared to vehicle treated 
tissue.  
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Fig. 1.7 CHA induced GDP/GTP exchange in the 
presence of A3AR agonist. Preincubation with Cl-IB-
MECA (n= 4,4 DMSO, Cl-IB-MECA) (A) did not 
decrease the hill slope of the 100pM-1µM dose range as 
would be expected if the A3AR stimulation was inducing 
the low hill slope at higher concentrations of CHA.  The 
presence or absence of Cl-IB-MECA had no effect on any 
pharmacological properties of CHA induced GDP/GTP 
exchange (B).  
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Discussion 
Torpor has been a topic of study for several decades. The mechanism that allows animals to enter 
torpor has yet to be determined. However, the A1AR has been shown to be critical for the safe 
expression of torpor. This study is the first to the author’s knowledge to conduct a 
comprehensive analysis of the binding characteristics of A1AR in the brain of summer and winter 
AGS.  
The affinity of adenosine receptor agonists can be species dependent (Klotz et al., 1991).  This 
makes it critical to define the basic binding parameters of agonists such as CHA in each 
individual species.  Direct ligand binding and competition assays have for the first time 
established Kd, Bmax, KiHi, Kilo, the fraction of receptors in the high and low affinity states in 
AGS brain tissue.  As expected [3H] DPCPX saturation experiments produced a one-site binding 
curve at the A1AR (Lohse et al., 1987).  Kd for DPCPX was similar to Kd’s reported in rat brain 
and smooth muscle preparations as well as sheep pineal membranes (León et al., 2004, Peachey 
et al,. 1994, Falcóna et al,. 1997).  Bmax for DPCPX binding was surprisingly consistent 
between brain regions in contrast to differences in Rmax of GTPγS binding. A functional assay 
such as GTPγS defines efficacy which may reflect the difference in functional surface receptors 
better than direct ligand binding.   
IC50lo and IC50Hi for CHA determined by displacing [
3H] DPCPX was similar for that found in 
mouse forebrain (Johansson et al., 1997). IC50 is not a constant and is not directly comparable 
due to its dependence on experimental conditions. The constant Ki could not be compared due to 
a lack of published data.  GTP produced a characteristic shift to a single site low affinity state 
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(Kilo) of the A1AR observed in CHA displacement of [
3H] DPCPX. In the absence of GTP a 2-
site model was consistent with agonist binding to high and low affinity states of the GPCR.  
CHA was found to induce GDP/GTP exchange as expected for an A1AR agonist as shown in rat 
brain tissue (Giuntini et al., 2004).  Binding characteristics of the hypothalamus and 
hippocampus indicated an increase in potency of CHA in the winter season. In the current study 
we report that the potency of CHA for A1AR in the winter season increased by 37 percent in the 
hypothalamus and by 31 percent in the hippocampus. In addition, the potency of PIA in the 
forebrain increased by 26 percent in the winter, which argues for a global sensitization of the 
A1AR in the AGS brain.  In the forebrain, an increase in potency during the winter season is 
explained by an increase in efficacy indicated by the fraction of receptors in the high affinity 
state. This interpretation was not consistent with results in the hypothalamus or hippocampus 
where there was a small but non-significant increase in the fraction of receptors in the high 
affinity state during the winter season. Interestingly, subsequent power analysis of the data 
indicated that a sample size of 15 AGS in each group would be sufficient to establish a 
difference in the fraction of receptors in the high affinity state in the hypothalamus, which would 
be consistent with the forebrain results. Power analysis also showed that a sample size of 20 
AGS in each group would be sufficient to establish a difference in the KiHi of CHA displacing 
[3H] DPCPX in both the forebrain and hippocampus. This data indicates that although there is a 
global change in the potency of CHA in the AGS brain, the means by which the shift in potency 
is achieved could be tissue specific. These conclusions will need to be further substantiated. The 
potential dual role of affinity and efficacy to influence the seasonal effect of an agonist could 
explain why PIA and not CHA showed the seasonal effect on potency. A detailed explanation of 
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the potential role of affinity and efficacy on individual agonist binding properties is beyond the 
scope of this paper.  
A lower Hill slope noted at higher concentrations of CHA could be due to a second binding site 
that was found to not be an A3AR site. Given that the A2BAR is not normally expressed in the 
brain and CHA has very low affinity for the A2AAR the second site is most likely not an 
adenosine receptor site.  The low Hill slope at higher concentrations of CHA could also be due to 
negative cooperativity that occurs when the A1AR form homomers (Gracia et al., 2013).  
Interestingly, inhibition of the A3AR leads to a decrease in the potency of CHA independent of 
season. This indicates possible positive cross-talk between the A1AR and the A3AR.  This 
conclusion was not supported by the stimulation of the A3AR which did not increase the potency 
of CHA. Considering that the A3AR is not being stimulated by CHA it is likely that the A3AR is 
already exerting a maximal effect on the A1AR. Therefore CHA potency at the A1AR would not 
increase by stimulating the A3AR.  
Adjustment of GDP/GTP exchange data to reflect the density of the A1AR would give an 
understanding of the functional receptors per total receptor pool. This could give an indication of 
the number of spare receptors in the system.  
In summary, evidence supports increased efficacy of CHA during the winter season due in part 
to an increase in the proportion of high affinity binding sites. Direct ligand binding and 
measurements of GDP/GTP exchange in AGS brain tissue yield results consistent with the 
behavior of the A1AR in other species. 
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Conclusions 
The A1AR has been shown to be critical in order for the AGS to enter the hibernation state. [
35S] 
GTPγS, [3H] DPCPX saturation and displacement assays were performed in order to ascertain the 
mechanisms that drive A1AR involvement in torpor. This work is the first to establish basic 
pharmacological parameters for A1AR CHA induced GDP/GTP exchange as well as KiHi and KiLo. 
Basic A1AR characterizations of [
3H] DPCPX binding such as Kd and Bmax were also established.  
The conclusion that an increase in efficacy is responsible for the increase in agonist potency during 
the winter season is one of several possible explanations. There are several additional explanations 
that could change agonist potency.  One possible explanation is that the A1AR undergoes 
modification by mRNA during the winter season which could change the potency. A second 
alternative explanation is that a change in the synergistic effects on the A1AR by other receptors 
and proteins are helping drive the seasonal change in potency.  
One potential reason why this study did not find an effect of season on the Kd, Bmax, KiHi or 
KiLo is because the AGS were euthanized while hibernating. In Jinka et al., 2011 the effect of 
CHA was investigated during interbout arousal. If the mechanisms that govern A1AR seasonal 
sensitivity are dynamic between the stages of hibernation then it is possible that an actively 
hibernating AGS would not demonstrate the seasonal effect. This research cannot address this 
possibility since tissues from both hibernating and interbout arousal animals was not available. It 
would be interesting to perform a similar study on animals during interbout arousal as well as 
during hibernation and the summer season.  
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A similar effect of CHA induced hibernation should be seen if there is an increase in the 
concentration of endogenous adenosine. During entrance into hibernation, it is possible that a 
sudden surge of adenosine acting on A1AR drives the entrance into hibernation.  For this reason it 
would be of interest to measure adenosine concentrations as well as binding parameters.  
A seasonal increase in potency was established for CHA in the hippocampus and hypothalamus.  
However, in the forebrain, PIA but not CHA demonstrated increased potency in the winter season. 
It is also interesting that the forebrain but not the hippocampus or hypothalamus demonstrated an 
increase in the fraction of receptors in the high affinity state. It has been well established that 
agonists can interact with a specific signaling path. If this is the case with PIA, this could indicate 
that discreet but different signaling pathways are being sensitized in order to facilitate the 
hibernation state.   
One requirement of the 35S-GTPγS binding experiment is the depletion of adenosine from the 
tissue. Since ADA has been shown to change ligand binding to the A1AR it is possible that the 
addition of ADA results in non-physiological data. It would therefore be of interest to determine 
binding parameters of CHA in tissue that was depleted of adenosine through a non-ADA method.   
In order to determine the possible synergistic influences on the A1AR during the summer and 
winter season a pull down assay could be utilized using the A1AR to capture interacting proteins. 
These proteins would then be analyzed by High-Pressure Liquid Chromatography or Time-of-
flight mass spectrometry. 
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Appendix A  
Isolating the Membrane Fraction from Brain Tissue 
 
This protocol details how to isolate the membrane fraction of brain tissue for use in [35S] 
Guanosine 5’-Triphosphate or Direct Ligand binding experiments.  
1. Prepare Protease Inhibitor Solution Containing; 
a. 10mM HEPES 
b. 2 IU/mL Adenosine Deaminase 
c. Roche protease inhibitor tablets  
2. Prepare Homogenization Buffer Containing; 
a. Protease Inhibitor Solution 
b. 636mM Sucrose 
3. Prepare Resuspension Buffer Containing; 
a. Protease Inhibitor solution 
4. Prepare GDP Incubation Buffer Containing; 
a. 50mM HEPES 
b. 100µM GDP 
c. 2 IU/mL Adenosine Deaminase 
5. Weigh tissue 
6. Homogenize in 20x volume of homogenization buffer 
a. Use an all glass dounce homogenizer 
7. Centrifuge at 1,000x gravity at 4⁰C for 5min.  
8. Centrifuge Supernant at 48,000xg for 15min at 4⁰C. 
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9. Resuspend pellet in 20x volume of resuspension buffer.  
10. Centrifuge at 48,000xg for 15min at 4⁰C 
11. Resuspend pellet in 20x volume of GDP incubation buffer.  
12. Incubate solution under gentle rocking at room temperature for 1h. 
13. Centrifuge at 48,000xg for 30min at 4⁰C 
14. Resuspend in 10x resuspending buffer. 
15. Determine protein concentration. 
16. Store at -80⁰C in single use aliquots.  
17. Centrifuge at 48,000xg for 30min at 4⁰C before use in binding experiments.  
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Appendix B 
35S-GTPγS: Protocol 
 
 
Optimal concentration steps modified from PerkinElmer Delfia System 
A. Optimal Concentration of MgCl2 and GDP for a 96 Well Plate 
Steps: 
1. Prepare all solutions on ice.  
2. Prepare a Buffer solution containing 
a. 50mM HEPES.  
b.  1 IU/mL Adenosine Deaminase  
c.  200mM NaCl  
d. 1mM Dithiothreitol 
3. All the following solutions should be prepared using the Buffer solution. 
4. Prepare four solutions containing between 5 and 75mM MgCl2. 
a. Concentration in well will be between 1 and 15mM MgCl2. 
b. 5, 15, 50 and 75mM MgCl2 worked well with the A1AR. 
5. Label the four solutions A, B, C and D 
6. Prepare four solutions containing between 0.5 and 200μM GDP 
a. Concentration in well will be between 0.1 and 40μM GDP. 
b. 25, 50, 100 and 200μM GDP worked well with the A1AR. 
7. Label these solutions GTP 1, 2, 3, 4 
8. Prepare 0 and 5x agonist solutions. 
a. Final concentration of 5x in well should be 100* the drugs Kd 
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9. Label these solutions Basal and Agonist. 
10. Prepare a membrane solution between 200 to 500μM*mL-1.  
a. Concentration in well will be between 4 and 10μM*mL-1. 
b. Check the plate guidelines for maximal protein allowed.  
11. Prepare an 2nM [35S]GTPγS solution. 
a. Final concentration in well should be 400pM 
12. Pipette 20μL of A into rows A and B. 
13. Pipette 20μL of B into rows C and D. 
14.  Pipette 20μL of C into rows E and F. 
15. Pipette 20μL of D into rows G and H. 
16. Pipette 20μL of GTP 1 into wells A (1-6), C (1-6), E (1-6) and G (1-6). 
17.  Pipette 20μL of GTP 2 into wells A (7-12), C (7-12), E (7-12) and G (7-12). 
18. Pipette 20μL of GTP 3 into wells B (1-6), D (1-6), F (1-6) and H (1-6). 
19.  Pipette 20μL of GTP 4 into wells B (7-12), D (7-12), F (7-12) and H (7-12). 
20. Pipette 20μL of basal in columns 1, 2, 3, 7, 8 and 9. 
21. Pipette 20μL of agonist solution into columns 4, 5, 6, 10, 11, and 12.  
22. Pipette 20μL of 2mM [35S]GTPγS solution into each well.  
23. Pipette 20μL of Membrane into each well.  
24. Incubate the plate for 90 minutes at 27 ⁰C under gentle rocking.  
25. Terminate the reaction by rapid vacuum filtration.  
26. Wash each well three times with 200μL of ice cold 50mM HEPES.  
27. Dry filter plate overnight. 
28. Add 40μL of microsintillation cocktail into each well. 
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29. Read plate using a 60 second count.  
30. Transform data from counts-per-minute into percent over basal. 
31.  Determine optimal MgCl2 and GDP concentration by graphing percent over basal 
data in a 3-D bar graph.  
B. Optimal Concentration of NaCl for a 96 Well Plate 
This experiment is designed to replicate the experiment on the same plate.  
1. Prepare all solutions on ice.  
2. Prepare Buffer solution containing  
a. 50mM HEPES 
b. 1 IU/mL Adenosine Deaminase 
c. 1mM Dithiothreitol 
d. Optimal concentration of MgCl2 
e. Optimal concentration of GDP 
3. Prepare all the following solutions in buffer 
4. Prepare seven different concentrations between 40 to 1000mM of NaCl  
a. Concentration in well will be 40 to 250mM NaCl 
b. 40, 80, 200, 400, 600, 800 and 1000mM worked well for the A1AR. 
5. Label these solutions A, B, C, D, E, F, G respectively  
6. Label an 8th solution H which will contain Buffer but no NaCl. 
7. Prepare a 0 and a 4x agonist solutions. 
a. The final concentration of agonist should be the same concentration as in step 
A. 
8. Label these solutions blank and agonist. 
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9. Prepare a membrane solution at the same concentration as in step A.  
10. Prepare an 1.6nM [35S]GTPγS solution. 
a. Final concentration in well should be 400pM 
11. Pipette 25µL of buffer into wells A (1-6) and E (1-6). 
12. Pipette 25µL of A into wells A (7-12) and E (7-12). 
13. Pipette 25µL of B into wells B (1-6) and F (1-6). 
14. Pipette 25µL of C into wells B (7-12) and F (7-12). 
15. Pipette 25µL of D into wells C (1-6) and G (1-6) 
16. Pipette 25µL of E into wells C (7-12) and G (7-12). 
17. Pipette 25µL of F into wells D (1-6) and H (1-6) 
18. Pipette 25µL of G into wells D (7-12) and H (7-12). 
19. Pipette 25µL of 0 agonist into columns 1-3 and 7-9. 
20. Pipette 25µL of 4x agonist into columns 4-6 and 10-12. 
21. Pipette 25µL of [35S]GTPγS into each well..  
22. Pipette 25µL of membrane solution into each well.  
23. Incubate the plate for 90 minutes at 27 ⁰C under gentle rocking.  
24. Terminate the reaction by rapid vacuum filtration.  
25. Wash each well three times with 200μL of ice cold 50mM HEPES.  
26. Dry filter plate overnight. 
27. Add 40μL of microsintillation cocktail into each well. 
28. Read plate using a 60 second count.  
29. Transform data from counts-per-minute into percent over basal. 
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30. Graph Concentration of NaCl vs Percent over basal to determine optimal 
concentration.  
C. Optimal Concentration of Saponin. 
This experiment is designed to replicate the experiment on the same plate.  
1. Prepare all solutions on ice.  
2. Prepare buffer solution containing  
a. 50mM HEPES 
b. 1 IU/mL Adenosine Deaminase 
c. 1mM Dithiothreitol 
d. Optimal concentration of MgCl2 
e. Optimal concentration of GDP 
f. Optimal concentration of NaCl 
3. Prepare all the following solutions in buffer.  
4. Prepare seven different solutions between 0.012 and 4mg*ml-1 of saponin. 
a. Concentration in well will be between 3 and 1000µg*ml-1. 
b. 0.012, 0.04, 0.12, 0.4, 1.2, 2.6 and 4mg*ml-1 works well for the A1AR. 
5. Label these solutions A, B, C, D, E, F and G.  
6. Label an 8th solution H which contains only buffer. 
7. Prepare a 0 and a 4x agonist solutions. 
a. The final concentration of agonist should be the same concentration as in step 
A. 
8. Label these basal and agonist.  
9. Prepare a membrane solution at the same concentration as in step A.  
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10. Prepare an 1.6nM [35S]GTPγS solution. 
a. Final concentration in well should be 400pM 
11. Pipette 25µL of buffer into wells A (1-6) and E (1-6). 
12. Pipette 25µL of A into wells A (7-12) and E (7-12). 
13. Pipette 25µL of B into wells B (1-6) and F (1-6). 
14. Pipette 25µL of C into wells B (7-12) and F (7-12). 
15. Pipette 25µL of D into wells C (1-6) and G (1-6) 
16. Pipette 25µL of E into wells C (7-12) and G (7-12). 
17. Pipette 25µL of F into wells D (1-6) and H (1-6) 
18. Pipette 25µL of G into wells D (7-12) and H (7-12). 
19. Pipette 25µL of 0 agonist into columns 1-3 and 7-9. 
20. Pipette 25µL of 4x agonist into columns 4-6 and 10-12. 
21. Pipette 25µL of [35S]GTPγS into each well..  
22. Pipette 25µL of membrane solution into each well.  
23. Incubate the plate for 90 minutes at 27 ⁰C under gentle rocking.  
24. Terminate the reaction by rapid vacuum filtration.  
25. Wash each well three times with 200μL of ice cold 50mM HEPES.  
26. Dry filter plate overnight. 
27. Add 40μL of microsintillation cocktail into each well. 
28. Read plate using a 60 second count.  
29. Transform data from counts-per-minute into percent over basal. 
30. Graph Concentration of saponin vs Percent over basal to determine optimal 
concentration.  
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D. Optimal Concentration of membrane.  
This experiment is designed to replicate the experiment on the same plate.  
1. Prepare all solutions on ice.  
2. Prepare buffer solution containing  
a. 50mM HEPES 
b. 1 IU/mL Adenosine Deaminase 
c. 1mM Dithiothreitol 
d. Optimal concentration of MgCl2 
e. Optimal concentration of GDP 
f. Optimal concentration of NaCl 
g. Optimal concentration of Saponin  
3. Prepare all the following solutions in buffer.  
4. Prepare seven different solutions of membrane between 40 and 480 µg*ml-1. 
a. Concentration in well will be between 10 and 120µg*ml-1. 
b. 10, 20, 40, 60, 80, 100 and 120µg*ml-1 works well for the A1AR. 
5. Label these solutions A, B, C, D, E, F and G.  
6. Label an 8th solution H which contains only Buffer. 
7. Prepare a 0 and a 4x agonist solutions. 
a. The final concentration of agonist should be the same concentration as in step 
A. 
8. Label these basal and agonist.  
9. Prepare a 1.6nM [35S]GTPγS solution. 
a. Final concentration in well should be 400pM 
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10. Pipette 25µL of Buffer into wells A (1-6) and E (1-6). 
11. Pipette 25µL of A into wells A (7-12) and E (7-12). 
12. Pipette 25µL of B into wells B (1-6) and F (1-6). 
13. Pipette 25µL of C into wells B (7-12) and F (7-12). 
14. Pipette 25µL of D into wells C (1-6) and G (1-6) 
15. Pipette 25µL of E into wells C (7-12) and G (7-12). 
16. Pipette 25µL of F into wells D (1-6) and H (1-6) 
17. Pipette 25µL of G into wells D (7-12) and H (7-12). 
18. Pipette 25µL of 0 agonist into columns 1-3 and 7-9. 
19. Pipette 25µL of 4x agonist into columns 4-6 and 10-12. 
20. Pipette 25µL of [35S]GTPγS into each well..  
21. Pipette 25µL of membrane solution into each well.  
22. Incubate the plate for 90 minutes at 27 ⁰C under gentle rocking.  
23. Terminate the reaction by rapid vacuum filtration.  
24. Wash each well three times with 200μL of ice cold 50mM HEPES.  
25. Dry filter plate overnight. 
26. Add 40μL of microsintillation cocktail into each well. 
27. Read plate using a 60 second count.  
28. Transform data from counts-per-minute into percent over basal. 
29. Graph Concentration of membrane vs Percent over basal to determine optimal 
membrane concentration.  
E. Determination of time to equilibrium.   
1. Prepare all solutions on ice.  
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2. Prepare buffer solution containing  
a. 50mM HEPES 
b. 1 IU/mL Adenosine Deaminase 
c. 1mM Dithiothreitol 
d. Optimal concentration of MgCl2 
e. Optimal concentration of GDP 
f. Optimal concentration of NaCl 
g. Optimal concentration of Saponin  
3. Prepare agonist solution at the same concentration as previous steps 
4. Prepare membrane solution at 4x optimal membrane concentration  
5. Prepare a 2nM [35S]GTPγS solution. 
6. Prepare a 20µM GTPγS solution. 
7. Choose 16 different time points over a 5h time period.  
a. For example 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 150, 180, 210, 240, and 
300min.  
8. Pipette 25µL of agonist solution into each well. 
9. Pipette 25µL of 1.6nM [35S]GTPγS solution into each well. 
10. Pipette 25µL of buffer into Columns 1-3, 10-12 
a. Label these columns total binding. 
11. Pipette 25µL of GTPγS into Columns 4-6, 7-9. 
a. Label these columns non-specific binding.  
12. Pipette 25µL of membrane solution into wells A (1-6) at time 0 min.  
13. Place plate on heater/shaker at 27 ⁰C and shake plate gently. 
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14.  Pipette 25µL of membrane solution into wells B (1-6) at time 60min.  
15. Pipette 25µL of membrane solution into wells C (1-6) at time 120 min.  
16. Pipette 25µL of membrane solution into wells E (1-6) at time 150 min.  
17. Pipette 25µL of membrane solution into wells F (1-6) at time 180 min.  
18. Pipette 25µL of membrane solution into wells G (1-6) at time 210 min.  
19. Pipette 25µL of membrane solution into wells H (1-6) at time 240 min.  
20. Pipette 25µL of membrane solution into wells A (7-12) at time 255 min.  
21. Pipette 25µL of membrane solution into wells B (7-12) at time 270 min.  
22. Pipette 25µL of membrane solution into wells C (7-12) at time 275 min.  
23. Pipette 25µL of membrane solution into wells D (7-12) at time 280 min.  
24. Pipette 25µL of membrane solution into wells E (7-12) at time 285 min.  
25. Pipette 25µL of membrane solution into wells F (7-12) at time 290 min.  
26. Pipette 25µL of membrane solution into wells G (7-12) at time 295 min.  
27. Pipette 25µL of membrane solution into wells H (7-12) at time 300 min.  
28. Remove plate from heater/shaker and terminate the reaction by rapid vacuum 
filtration.  
29. Wash each well three times with 200μL of ice cold 50mM HEPES.  
30. Dry filter plate overnight. 
31. Add 40μL of microsintillation cocktail into each well. 
32. Read plate using a 60 second count.  
33. Determine specific binding.  
34. Determine time to equilibrium by graphing time vs specific CPM.  
F. Determination of Dose-Response Range.   
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1. Prepare all solutions on ice.  
2. Prepare buffer solution containing  
a. 50mM HEPES 
b. 1 IU/mL Adenosine Deaminase 
c. 1mM Dithiothreitol 
d. Optimal concentration of MgCl2 
e. Optimal concentration of GDP 
f. Optimal concentration of NaCl 
g. Optimal concentration of Saponin  
3. Prepare 15 different agonist solutions between 1pM and 1mM.   
a. For N6-Cyclohexyl Adenosine 2, 4, 40, 200, 400pM, 2, 4, 40, 200, 400nM and 
2, 4, 40, 200 and 400µM worked well.  
b. Label these solutions A-O 
4. Prepare a solution with only buffer and label it basal.  
5. Prepare membrane solution at 4x optimal membrane concentration  
6. Prepare a 1.6nM [35S]GTPγS solution. 
7. Prepare a 20µM GTPγS solution. 
8. Pipette 25µL of basal into A (1-6). 
9. Pipette 25µL of O into B (1-6). 
10. Pipette 25µL of N into C (1-6). 
11. Pipette 25µL of M into D (1-6). 
12. Pipette 25µL of L into E (1-6). 
13. Pipette 25µL of K into F (1-6). 
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14. Pipette 25µL of J into G (1-6). 
15. Pipette 25µL of I into H (1-6). 
16. Pipette 25µL of H into A (7-12). 
17. Pipette 25µL of G into B (7-12). 
18. Pipette 25µL of F into C (7-12). 
19. Pipette 25µL of E into D (7-12). 
20. Pipette 25µL of D into E (7-12). 
21. Pipette 25µL of C into F (7-12). 
22. Pipette 25µL of B into G (7-12). 
23. Pipette 25µL of A into H (7-12). 
24. Pipette 25µL of 1.6nM [35S]GTPγS solution. 
25. Pipette 25µL of buffer into columns 1-3 and 9-12. 
a. Label these columns total binding. 
26. Pipette 25µL of GTPγS solution into columns 4-6 and 7-9. 
a. Label these columns non-specific binding. 
27. Pipette 25µL of membrane solution into every well. 
28. Incubate plate for time determined from step E at 27 ⁰C under gentle rocking. 
29. Terminate the reaction by rapid vacuum filtration.  
30. Wash each well three times with 200μL of ice cold 50mM HEPES.  
31. Dry filter plate overnight. 
32. Add 40μL of microsintillation cocktail into each well. 
33. Read plate using a 60 second count.  
34. Determine specific binding and then percent over basal.   
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35.  Graph Percent over basal vs. the log of the concentration. 
36. Determine an eight point dose rage from graph.  
G. [35S]GTPγS Binding Protocol with modifications from Cooper, T. et al. G Protein-
Coupled Receptors in Drug Discovery Vol. 552.  Chapter 10. Edited by Leifert, W.R. 
This protocol is designed to repeat the experiment on the same plate.  
1. Prepare all solutions on ice.  
2. Prepare buffer solution containing  
a. 50mM HEPES 
b. 1 IU/mL Adenosine Deaminase 
c. 1mM Dithiothreitol 
d. Optimal concentration of MgCl2 
e. Optimal concentration of GDP 
f. Optimal concentration of NaCl 
g. Optimal concentration of Saponin  
3. Prepare each of the following solutions in Buffer. 
4. Prepare 7 different agonist solutions determined from step F. 
a. Label these A-G 
5. Prepare an aliquot of buffer and label it Basal.  
6. Prepare membrane solution at 4x optimal membrane concentration  
7. Prepare a 1.6nM [35S]GTPγS solution. 
8. Prepare a 20µM GTPγS solution. 
9. Pipette 25µL of Basal into A (1-6 and 7-12). 
10. Pipette 25µL of G into B (1-6 and 7-12). 
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11. Pipette 25µL of F into C (1-6 and 7-12). 
12. Pipette 25µL of E into D (1-6 and 7-12). 
13. Pipette 25µL of D into E (1-6 and 7-12). 
14. Pipette 25µL of C into F (1-6 and 7-12). 
15. Pipette 25µL of B into G (1-6 and 7-12). 
16. Pipette 25µL of A into H (1-6 and 7-12). 
17.  Pipette 25µL of Buffer into columns 1-3 and 9-12. 
a. Label these columns total binding. 
18. Pipette 25µL of GTPγS solution into columns 4-6 and 7-9. 
b. Label these columns non-specific binding. 
19. Pipette 25µL of membrane solution into every well. 
20. Incubate plate for time determined from step E at 27 ⁰C under gentle rocking. 
21. Terminate the reaction by rapid vacuum filtration.  
22. Wash each well three times with 200μL of ice cold 50mM HEPES.  
23. Dry filter plate overnight. 
24. Add 40μL of microsintillation cocktail into each well. 
25. Read plate using a 60 second count.  
26. Determine specific binding and then percent over basal.   
27.  Graph Percent over basal vs. the log of the concentration. 
H. [35S]GTPγS Binding Protocol with Second Agonist or Antagonist.  
1. Prepare all solutions ice.  
2. Repeat step E but this time incubate the membrane for 60min with the 100x the Kd of 
the agonist or antagonist.  
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3. Prepare buffer solution containing  
a. 50mM HEPES 
b. 1 IU/mL Adenosine Deaminase 
c. 1mM Dithiothreitol 
d. Optimal concentration of MgCl2 
e. Optimal concentration of GDP 
f. Optimal concentration of NaCl 
g. Optimal concentration of Saponin  
4. Prepare each of the following solutions in Buffer 
5. Prepare 7 different agonist solutions determined from step F. 
h. Label these A-G 
6. Prepare an aliquot of buffer and label it Basal.  
7. Prepare membrane solution at a higher concentration then 4x the optimal membrane 
concentration  
8. Split the membrane into two equal aliquots of known volume. 
9. Label these aliquots Membrane A and Membrane B.  
10. Add appropriate amount of drug into Membrane A and dilute to proper membrane 
concentration.   
11. Add appropriate amount of buffer to Membrane B to optimal membrane 
concentration.  
12. Incubate the membranes at 4◦C for 60min. 
13. Prepare a 1.6nM [35S]GTPγS solution. 
14. Prepare a 20µM GTPγS solution. 
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15. Pipette 25µL of Basal into A (1-6 and 7-12). 
16. Pipette 25µL of G into B (1-6 and 7-12). 
17. Pipette 25µL of F into C (1-6 and 7-12). 
18. Pipette 25µL of E into D (1-6 and 7-12). 
19. Pipette 25µL of D into E (1-6 and 7-12). 
20. Pipette 25µL of C into F (1-6 and 7-12). 
21. Pipette 25µL of B into G (1-6 and 7-12). 
22. Pipette 25µL of A into H (1-6 and 7-12). 
23.  Pipette 25µL of buffer into columns 1-3. 
a. Label these columns total binding. 
24. Pipette 25µL of buffer into columns 10-12. 
a. Label these columns total binding w/ agonist (or antagonist) 
25. Pipette 25µL of GTPγS solution into columns 4-6. 
a. Label these columns non-specific binding. 
26. Pipette 25µL of GTPγS solution into columns 7-9. 
b. Label these columns non-specific binding w/ agonist (or antagonist). 
27. Pipette 25µL of Membrane B solution into columns 1-6.  
28. Pipette 25µL of Membrane A solution into columns 7-12. 
29. Incubate plate for time determined from step 1 of this experiment at 27 ⁰C under 
gentle rocking. 
30. Terminate the reaction by rapid vacuum filtration.  
31. Wash each well three times with 200μL of ice cold 50mM HEPES.  
32. Dry filter plate overnight. 
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33. Add 40μL of microsintillation cocktail into each well. 
34. Read plate using a 60 second count.  
35. Determine specific binding and then percent over basal.   
36.  Graph Percent over basal vs. the log of the concentration. 
a. Graph the w/ agonist or antagonist data using the basal binding from wells A 
(1-3). 
b. The w/ agonist or antagonist basal is useful to determine the effect on the 
system in the absence of the first agonist.  
37. Use this data to determine the effect of the secondary agonist/antagonist on the 
original agonist.  
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Appendix C 
Optimization of 35S-GTPγS binding  
 
 
 
Fig. C.1 The optimization of MgCl2 and GDP for 
35S-GTPγS binding. Optimal 
concentrations of MgCl2 and GDP were determined to be 10mM and 40μM respectively.  
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Fig. C.2 The optimization of NaCl for 35S-GTPγS binding. The optimal 
concentration of NaCl was determined to be 200mM. 
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Fig. C.3 The optimization of saponin for 35S-GTPγS binding. Optimal concentration of 
saponin was determined to be 100μg*ml-1.  
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Fig. C.4 The optimization of protein concentration for 35S-GTPγS binding. Optimal 
concentration of membrane was determined to be 10μg*well-1. 12 μg*well-1 gave a 
higher signal but was not used due to the capacity of the filter plate.  
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Appendix D 
Binding kinetics of 35S-GTPγS and [3H] DPCPX 
 
Fig.D.1 Time to equilibrium for CHA and PIA, 35S-GTPγS binding kinetics. Time to 
equilibrium for agonist induced GDP/GTP exchange was determined to be 90 minutes in 
the presence of either CHA (squares) or PIA (diamonds). 
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Fig. D.2 CHA equilibrium time with A3AR antagonist, 
35S-GTPγS binding kinetics. Time 
for CHA induced GDP/GTP exchange to reach equilibrium in the presence of MRS-1334 
was determined to be 90 minutes.  
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Fig. D.3 CHA equilibrium time in the presence of A3AR agonist, 
35S-GTPγS binding 
kinetics. Time for CHA induced GDP/GTP exchange to reach equilibrium in the 
presence of Cl-IB-MECA was determined to be 2.5h.  
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Fig. D.4 Displacement of [3H] DPCPX with 1µM of Cl-IB-MECA. The 
displacement of [3H] DPCPX with 1µM of IB-MECA. T1/2 was determined to be 
5.6 minutes.  
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Fig. D.5 Time to equilibrium for the displacement of [3H] DPCPX by 20pM CHA .The minimum 
time to equilibrium for the displacement of [3H] DPCPX by 20pM CHA was determined to be 30 
minutes.  
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Fig. D.6 Equilibrium time for CHA displacement of [3H] DPCPX  with or without GTP. The 
time to equilibrium for CHA displacing DPCPX in the presence (triangles, solid line) and 
absence of 1mM of GTP (squares, dotted line) was determined to be 30 minutes.  
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Appendix E 
Direct Ligand Binding: Protocol 
 
A. Determination of membrane concentration.  
Steps: 
1. Prepare all solutions on ice.  
2. Prepare a Buffer solution containing 
a. 50mM HEPES.  
b.  1 IU/mL Adenosine Deaminase  
3. Prepare each of the following solutions in buffer.  
4. Prepare a solution of 4x radioactive ligand. 
a. The concentration in the well should be 1-10x the Kd of the radioactive 
ligand.  
5. Prepare a solution of 4x non-radioactive ligand to determine non-specific binding. 
a. The concentration in the well should be 100x the Kd of the cold ligand. 
6. Prepare 15 different concentrations of membrane. 
a. Remember that each membrane solution should be 4x the desired 
concentration. 
b. Label these Membrane A-O. 
7. Prepare an aliquot of buffer and label this Membrane P. 
8. Pipette 25µL of buffer into each well. 
9. Pipette 25µL of radioactive ligand into each well. 
10. Pipette 25µL of buffer into columns 1-3 and 10-12. 
a. Label these columns total binding. 
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11. Pipette 25µL of non-radioactive ligand into columns 4-9. 
a. Label these columns non-specific binding. 
12. Pipette 25µL of Membrane P into wells A (1-6). 
13. Pipette 25µL of Membrane O into wells B (1-6). 
14. Pipette 25µL of Membrane N into wells C (1-6). 
15. Pipette 25µL of Membrane M into wells D (1-6). 
16. Pipette 25µL of Membrane L into wells E (1-6). 
17. Pipette 25µL of Membrane K into wells F (1-6). 
18. Pipette 25µL of Membrane J into wells G (1-6). 
19. Pipette 25µL of Membrane I into wells H (1-6). 
20. Pipette 25µL of Membrane H into wells A (7-12). 
21. Pipette 25µL of Membrane G into wells B (7-12). 
22. Pipette 25µL of Membrane F into wells C (7-12). 
23. Pipette 25µL of Membrane E into wells D 7-12). 
24. Pipette 25µL of Membrane D into wells E (7-12). 
25. Pipette 25µL of Membrane C into wells F (7-12). 
26. Pipette 25µL of Membrane B into wells G (7-12). 
27. Pipette 25µL of Membrane A into wells H (7-12). 
28. Incubate plate at room temperature for 30-90min 
a. Determine the time based on literature reviews. 
29. Filter solution through an all glass filter pad using a cell harvester. 
30. Remove the filter and allow to dry overnight. 
31. Cut individual wells out of the filter and place them into a scintillation vial. 
  71  
 
32. Add scintillation cocktail to each scintillation vial.  
33. Read the plate in a scintillation counter using a 5min counting time.  
34. Subtract non-specific binding from total binding to determine specific binding.  
35. Graph results in specific binding vs. membrane concentration. 
36. Choose the membrane concentration that gets the most signal off of the least amount 
of membrane.  
B. Determination of the Koff of the Radioactive Ligand (time to equilibrium for Kd 
experiments).  
Steps: 
1. Prepare all solutions on ice.  
2. Prepare a buffer solution containing 
a. 50mM HEPES.  
b.  1 IU/mL Adenosine Deaminase  
3. Prepare each of the following solutions in Buffer.  
4. Prepare a solution of 4x radioactive ligand. 
a. The concentration in the well should be 1-10x the Kd of the radioactive 
ligand.  
5. Prepare a solution of 4x non-radioactive ligand to determine non-specific binding. 
a. The concentration in the well should be 100x the Kd of the cold ligand.  
6. Prepare a 4x membrane solution based on membrane optimization experiment.  
7. Choose 32 time points. 
a. Look at the literature to determine the appropriate range.  
8. Pipette 25µL of Buffer into each well. 
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9. Pipette 25µL of Radioactive Ligand into each well. 
10. Pipette 25µL of Membrane into each well. 
11. Incubate plate for one to two hours.  
12. Pipette 25µL of non-radioactive ligand into A(1-3). 
a. The first wells that receive non-radioactive ligand will correspond to the last 
time point in your experiment.  
13. Continue pipetting 25µL of non-radioactive ligand at each of your chosen time points.  
14. Filter the reaction with cell harvester utilizing an all glass filter.  
15. Remove glass filter from cell harvester and dry overnight. 
16. Cut individual wells out of the glass filter and place into a scintillation vial. 
17. Fill scintillation vials with scintillation cocktail.  
18. Read in a scintillation counter with a 5min counting time.  
19. Insert data into Graphpad Prism. 
20. Calculate the Koff and then the t1/2. 
21. The incubation time is equal to 5x t1/2. 
C. Determination of the radioactive ligand binding parameters.   
Steps: 
1. Prepare all solutions on ice.  
2. Prepare a buffer solution containing 
a. 50mM HEPES.  
b.  1 IU/mL Adenosine Deaminase  
3. Make each of the following solutions using the Buffer.  
4. Prepare 15 solutions of radioactive ligand between pM and µM concentrations.  
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a. This range should be determined by an extensive literature review.  
b. Label these RL 1-15.  
5. Prepare an aliquot of buffer and label it RL 16 
6. Prepare a solution of 4x non-radioactive ligand to determine non-specific binding. 
a. The concentration in the well should be 100x the Kd of the cold ligand.  
7. Prepare a 4x membrane solution based on the membrane optimization experiment. 
8.  Pipette 25µL of buffer into columns 1-3 and 10-12. 
a. Label these columns total binding. 
9. Pipette 25µL of non-radioactive ligand into columns 4-9. 
b. Label these columns non-specific binding. 
10. Pipette 25µL of RL 16 into wells A (1-6). 
11. Pipette 25µL of RL 15 into wells B (1-6). 
12. Pipette 25µL of RL 14 into wells C (1-6). 
13. Pipette 25µL of RL 13 into wells D (1-6). 
14. Pipette 25µL of RL 12 into wells E (1-6). 
15. Pipette 25µL of RL 11 into wells F (1-6). 
16. Pipette 25µL of RL 10 into wells G (1-6). 
17. Pipette 25µL of RL 9 into wells H (1-6). 
18. Pipette 25µL of RL 8 into wells A (7-12). 
19. Pipette 25µL of RL 7 into wells B (7-12). 
20. Pipette 25µL of RL 6 into wells C (7-12). 
21. Pipette 25µL of RL 5 into wells D (7-12). 
22. Pipette 25µL of RL 4 into wells E (7-12). 
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23. Pipette 25µL of RL 3 into wells F (7-12). 
24. Pipette 25µL of RL 2 into wells G (7-12). 
25. Pipette 25µL of RL 1 into wells H (7-12). 
26. Incubate plate at room temperature for the time determined in the above experiment.  
27. Filter solution through an all glass filter pad using a cell harvester. 
28. Remove the filter and allow to dry overnight. 
29. Cut individual wells out of the filter and place them into a scintillation vial. 
30. Add scintillation cocktail to each scintillation vial.  
31. Read the plate in a scintillation counter using a 5min counting time.  
32.  Determine binding parameters of the radioactive ligand using Graphpad Prism.  
33. Repeat the experiment with a modified range if the concentrations of radioactive 
ligand were not correct.  
D. Determination of the time to equilibrium of a radioactive ligand in the presence of a 
competitive ligand.  
Steps: 
1. Prepare all solutions on ice.  
2. Prepare a buffer solution containing 
a. 50mM HEPES.  
b.  1 IU/mL Adenosine Deaminase  
3. Prepare all the following solutions in Buffer.  
4. Prepare a solution of 4x radioactive ligand. 
a. The concentration in the well should be 1-10x the Kd of the radioactive 
ligand.  
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5. Prepare a solution of 4x non-radioactive ligand to determine non-specific binding. 
a. The concentration in the well should be 100x the Kd of the cold ligand.  
6. Prepare a solution of your competitive ligand at the lowest concentration you plan to 
test.  
a. The less competitive ligand the longer it takes to equilibrium.  
7. Prepare a 4x membrane solution based on membrane optimization experiment.  
8. Choose 32 time points. 
a. Look at the literature to determine an appropriate range.  
9. Pipette 25µL of buffer into each well.  
10. Pipette 25µL of radioactive ligand into each well. 
11. Pipette 25µL of competitive agonist into each well.  
12. Pipette 25µL of membrane into well A (1-3).  
a. These wells will be incubated the longest.  
13. Continue pipetting 25µL of membrane at each of your chosen time points.  
14. Immediately filter the reaction through an all glass filter using the cell harvester.   
15. Remove glass filter from cell harvester and dry overnight. 
16. Cut individual wells out of the glass filter and place into a scintillation vial. 
17. Fill scintillation vials with scintillation cocktail.  
18. Read in a scintillation counter with a 5min counting time.  
19. Graph the specific binding vs. time in order to determine the time it takes to reach 
equilibrium. 
E. Competitive Direct Ligand Binding the Determination of the Dose Response Range. 
Steps: 
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1. Prepare all solutions on ice.  
2. Prepare a buffer solution containing 
a. 50mM HEPES.  
b.  1 IU/mL Adenosine Deaminase  
3. Prepare all the following solutions in Buffer. 
3.  Prepare a solution of 4x radioactive ligand. 
a. The concentration in the well should be 1-10x the Kd of the radioactive ligand. 
4. Prepare a solution of 4x non-radioactive ligand to determine non-specific binding. 
a. The concentration in the well should be 100x the Kd of the cold ligand.  
5. Prepare 15 different solutions of your competitive ligand from pM to µM 
concentrations.  
a. This range should be based on a literature review.  
b. Label these solutions A-O. 
6. Prepare an aliquot of buffer and label it P. 
7. Pipette 25µL of radioactive ligand into each well.  
8. Pipette 25µL of radioactive ligand into three different scintillation vials. 
a. This will be used to determine the concentration of the radioactive ligand.  
b. Label these C1, C2, and C3 
9. Pipette 25µL of buffer into columns 1-3 and 10-12. 
a. Label these columns total binding. 
10. Pipette 25µL of non-radioactive drug into columns 4-9.  
a. Label these columns non-specific binding.  
11. Pipette 25µL of P into wells A (1-6). 
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12. Pipette 25µL of O into wells B (1-6). 
13. Pipette 25µL of N into wells C (1-6). 
14. Pipette 25µL of M into wells D (1-6). 
15. Pipette 25µL of L into wells E (1-6). 
16. Pipette 25µL of K into wells F (1-6). 
17. Pipette 25µL of J into wells G (1-6). 
18. Pipette 25µL of I into wells H (1-6). 
19. Pipette 25µL of H into wells A (7-12). 
20. Pipette 25µL of G into wells B (7-12). 
21. Pipette 25µL of F into wells C (7-12). 
22. Pipette 25µL of E into wells D 7-12). 
23. Pipette 25µL of D into wells E (7-12). 
24. Pipette 25µL of C into wells F (7-12). 
25. Pipette 25µL of B into wells G (7-12). 
26. Pipette 25µL of A into wells H (7-12). 
27. Pipette 25µL of membrane solution into each well.  
28. Incubate plate for the time you determined in step D. 
29. Filter the reaction through an all glass filter using the cell harvester.   
30. Remove glass filter from cell harvester and dry overnight. 
31. Cut individual wells out of the glass filter and place into a scintillation vial. 
32. Fill the scintillation vials along with C1, C2  and C3 with scintillation cocktail.  
33. Read in a scintillation counter with a 5min counting time.  
34. Subtract non-specific binding from total binding. 
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35. Enter data into Graphpad Prism to determine competitive binding parameters.  
36. You will need the concentration of your radioactive ligand and the Kd from 
experiment C to find the Ki.  
F. Direct ligand Binding, Competitive Direct Ligand Binding and GTP Shift on One Plate. 
Steps: 
1. Prepare all solutions on ice.  
2. Prepare a buffer solution containing 
a. 50mM HEPES.  
b.  1 IU/mL Adenosine Deaminase  
3. Prepare all the following solutions in buffer. 
4.  Prepare a solution of 4x radioactive ligand. 
a. The concentration in the well should be 1-10x the Kd of the radioactive ligand. 
5. Prepare a range of 9 other radioactive ligand solutions based on experiment C.  
a. Label these solutions RL 1-9 
6. Prepare an aliquot of buffer and label it RL 10 
7. Prepare a solution of 4x non-radioactive ligand to determine non-specific binding. 
a. The concentration in the well should be 100x the Kd of the cold ligand.  
8. Prepare 9 different solutions of your competitive ligand determined from step E.  
a. Label these A-I. 
9. Prepare an aliquot of buffer label it J. 
10. Prepare a 4mM GTP solution.  
11. Prepare a 4x membrane solution. 
12. Pipette 25µL of radioactive ligand into Columns 1-6 and A-F (7-9). 
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13. Pipette 25µL of radioactive ligand into three scintillation vials.  
a. These will be used to determine the concentration of radioactive ligand.  
b. Label these Z1, Z2, and Z3. 
14. Pipette 25µL of J into wells A (1-3) and E (4-6). 
15. Pipette 25µL of I into wells B (1-3) and F (4-6). 
16. Pipette 25µL of H into wells C (1-3) and G (4-6). 
17. Pipette 25µL of G into wells D (1-3) and H (4-6). 
18. Pipette 25µL of F into wells E (1-3) and A (7-9). 
19. Pipette 25µL of E into wells F (1-3) and B (7-9). 
20. Pipette 25µL of D into wells G (1-3) and C (7-9). 
21. Pipette 25µL of C into wells H (1-3) and D (7-9). 
22. Pipette 25µL of B into wells A (1-3) and E (7-9). 
23. Pipette 25µL of A into wells B (1-3) and F (7-9). 
24. Pipette 25µL of buffer into columns 1-3 and wells A and B (4-6). 
a. This is the competitive binding experiment.  
25. Pipette 25µL of 4mM GTP solution into wells E-H (4-6) and A-F (7-9). 
a. This is the GTP shift experiment.  
26. Pipette 25µL of buffer into wells C (4-6). 
27. Pipette 25µL of 4mM GTP into wells D (4-6). 
28. Pipette 25µL of non-radioactive ligand into C, D (4-6). 
a. These well are the non-specific binding for the displacement experiment with and 
without GTP.  
29. Pipette 25µL of buffer into wells G and H (7-9) and columns 10-12.  
  80  
 
30. Pipette 25µL of RL 10 into wells G (7-9). 
31. Pipette 25µL of RL 9 into wells H (7-9). 
32. Pipette 25µL of RL 8 into wells A (10-12). 
33. Pipette 25µL of RL 7 into wells B (10-12). 
34. Pipette 25µL of RL 6 into wells C (10-12). 
35. Pipette 25µL of RL 5 into wells D (10-12). 
36. Pipette 25µL of RL 4 into wells E (10-12). 
37. Pipette 25µL of RL 3 into wells F (10-12). 
38. Pipette 25µL of RL 2 into wells G (10-12). 
39. Pipette 25µL of RL 1 into wells H (10-12). 
40. Pipette 25µL of buffer into wells G, H (7, 8) and columns 10 and 11.  
a. These wells will be your total binding for the direct ligand binding experiment. 
41. Pipette 25µL of non-radioactive ligand into G, H (9) and column 12. 
a. These wells are the non-specific binding for the direct ligand binding experiment.  
42. Pipette 25µL of Membrane into each well.  
a. Use a different syringe for each experiment.  
43.  Incubate plate at room temperature for length of time indicated in D.  
44. Filter the reaction through an all glass filter using the cell harvester.   
45. Remove glass filter from cell harvester and dry overnight. 
46. Cut individual wells out of the glass filter and place into a scintillation vial. 
47. Fill scintillation vials with scintillation cocktail including C1, C2 and C3.  
48. Read in a scintillation counter along with C1, C2, and C3 with a 5min counting time.  
49.  Determine the concentration of your radioactive ligand solution, 
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50. Determine the Kd of your radioactive ligand. 
51. Use the Kd and concentration of radioactive ligand to determine the Ki with and 
without GTP. 
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Appendix F 
[3H] DPCPX saturation and displacement in summer and winter AGS 
 
 
 
Fig. F.1 [3H] DPCPX saturation binding kinetics in AGS brain. [3H] DPCPX saturation binding 
kinetics in AGS forebrain, hippocampus and hypothalamus in the summer (A,C,E) and winter 
(B,D,F) season. Season had no effect on [3H] DPCPX binding. 
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Fig. F.2 Kinetics of [3H] DPCPX displacement by CHA in AGS brain. Competition curve 
showing the displacement of 1nM of [3H] DPCPX by various concentrations of CHA in AGS 
forebrain, hippocampus and hypothalamus in the summer (A,C,E) and winter (B,D,F). 
Results indicate a statistical difference in the fraction of receptors in the high affinity state 
(ReceptorHigh). * indicate a statistical difference within the same tissue (p < 0.05). Although 
there were no further differences between the summer and winter season, the winter season 
tended to have a lower KiHigh and greater ReceptorHigh.
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Fig. F.3 Kinetics of [3H] DPCPX displacement by CHA in AGS brain in the presence of GTP. 
Competition curve showing the displacement of 1nM of [3H]DPCPX, in the presence of 1µM 
GTP, by various concentrations of CHA in AGS forebrain, hippocampus  and hypothalamus in 
the summer (A,C,E) and winter (B,D,F). The displacement curves depict one site binding 
isotherms which is indicative of the loss of G-protein coupling.  
